Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • dose reduction
Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission
Posted inClinical Updates news Psychiatry Specialties

Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission

Posted by MedXY By MedXY 10/01/2025
A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.
Read More
Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?
Posted inClinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

Posted by MedXY By MedXY 09/25/2025
Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.
Read More
Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial
Posted inClinical Updates news Oncology Radiology Specialties

Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial

Posted by MedXY By MedXY 08/07/2025
The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.
Read More
  • Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial
  • Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease
  • Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16
  • PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
  • Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in